Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the
Novartis International AG / Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease processed and transmitted by Hugin AS.
Swiss drug maker Novartis AG said Tuesday that its experimental meningitis vaccine performed well in a large clinical trial and that the company expects to file it for regulatory approval in the US and Europe this year.